PTC offers high-end computer-assisted design (Creo) and product lifecycle management (Windchill) software as well as Internet of Things and AR industrial solutions. Founded in 1985, PTC has 28,000 cus ...

PTC Therapeutics has abandoned its latest attempt to secure FDA approval for Duchenne muscular dystrophy (DMD) treatment Translarna, after the FDA said it was unlikely to approve the drug based on the ...

On February 26, 2026, PTC Inc. announced a fully cloud-native Model-Based Definition capability embedded in its Onshape CAD and PDM platform, enabling engineering teams to keep manufacturing ...

PTC Inc. PTC has unveiled a fully cloud-native Model-Based Definition (MBD) capability integrated directly into its Onshape ...

PTC Industries’ (PTCIL) Q3FY26 EBITDA grew 62% YoY to INR 248mn (-4% YoY) aided by more-than-double sales growth. ATL and TARC registered good top-line growth but margins were under pressure due to ...

It is currently unclear if PTC plans to re-file for Translarna’s US approval in DMD. Image credit: Michael Vi via ShutterStock.com. PTC Therapeutics has chosen to withdraw its resubmitted new drug ...

With the writing apparently on the wall, PTC Therapeutics has called off its latest bid for FDA approval of its Duchenne muscular dystrophy (DMD) drug Translarna. Late Thursday, PTC revealed that it ...

USA-based rare disease drug developer PTC Therapeutics (Nasdaq: PTCT) saw its shares drop 5.2% to $67.05 after market close, when it announced that it has withdrawn the New Drug Application (NDA) ...